News
RFL
1.640
+1.23%
0.020
BRIEF-Rafael Holdings Reports Q2 Fiscal 2023 Financial Results
Reuters · 03/14 21:36
Rafael Holdings GAAP EPS of -$0.14, revenue of $0.07M
Seeking Alpha · 03/14 21:27
Rafael Holdings Q2 EPS $(0.14) Down From $(0.12) YoY
Benzinga · 03/14 20:02
Top Real Estate Stocks That May Plunge
Benzinga · 02/17 12:02
BRIEF-Protara Therapeutics Announces Appointment Of Patrick Fabbio As CFO
Reuters · 01/30 14:45
Protara Therapeutics Names Patrick Fabbio Financial Chief
Protara Therapeutics Names Patrick Fabbio Financial Chief
MT Newswires · 01/30 09:52
Rafael Says Effective Jan. 27, 2023 Chief Financial Officer Patrick Fabbio To Depart Co.
Benzinga · 01/05 21:53
BRIEF-Rafael Holdings Inc - Effective January 27, 2023, Patrick Fabbio, Current Chief Financial Officer Of Company, Would Be Departing Company
Reuters · 01/05 21:53
BRIEF-Rafael Holdings Reports Q1 Loss Per Share Of $0.22
Reuters · 12/13/2022 12:41
Rafael Holdings Q1 EPS $(0.22) Up From $(0.75) YoY
Benzinga · 12/13/2022 12:07
Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022. “We are pleased to have successfully completed the sale of our re...
GlobeNewswire · 12/13/2022 12:00
Rafael stepping back from early-stage development in favor of acquisition, licensing
Seekingalpha · 11/16/2022 16:27
Rafael Holdings To Focus On Strategic Business Development Initiatives And Curtail Early Stage Development Activities; As Of July 31, 2022, The Company Held Cash, Cash Equivalents And Marketable Securities Of $63.2M
Benzinga · 11/15/2022 21:03
BRIEF-Rafael Holdings To Focus On Strategic Business Development Initiatives, Curtail Early Stage Development Activities
Reuters · 11/15/2022 21:02
"Rafael Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 17/261,237 Titled 'Therapeutic Methods And Compositions For Treating Pancreatic Cancer Using 6,8-BIS-BENZYLTHIO-OCTANOIC ACID'" - USPTO
Benzinga · 11/08/2022 16:39
BRIEF-Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results
Reuters · 10/31/2022 22:09
Rafael Holdings GAAP EPS of -$0.24, revenue of $69K
Seekingalpha · 10/31/2022 21:30
Rafael Holdings Q4 EPS $(0.24) Up From $(0.75) YoY
Benzinga · 10/31/2022 20:14
BRIEF-Cornerstone Pharmaceuticals Initiates Phase 1 Trial Of CPI-613 In Combination With Chemoradiation For Treatment Of Advanced Pancreatic Cancer
BRIEF-Cornerstone Pharmaceuticals Initiates Phase 1 Trial Of CPI-613 In Combination With Chemoradiation For Treatment Of Advanced Pancreatic Cancer
Reuters · 09/28/2022 11:15
Cornerstone Pharmaceuticals Starts Pancreatic Cancer Trial of Devimistat
Cornerstone Pharmaceuticals Starts Pancreatic Cancer Trial of Devimistat
MT Newswires · 09/28/2022 07:58
More
Webull provides a variety of real-time RFL stock news. You can receive the latest news about Rafael Holdings through multiple platforms. This information may help you make smarter investment decisions.
About RFL
Rafael Holdings, Inc. is a holding company. The Company owns interests in clinical and early-stage pharmaceutical companies and commercial real estate assets. The Company is focused on the discovery of cancer and immune metabolism therapeutics. The Company operates through two segments: Pharmaceuticals and Real Estate. The Pharmaceuticals segment is comprised of preferred and common equity interests and the Warrant to purchase equity interests in Rafael Pharmaceuticals, a majority equity interest in LipoMedix, Barer, Levco, Farber and Rafael Medical Devices. The Real Estate segment consists of the Company's real estate holdings associated with a portion of an office building in Israel.